How do you see the quarterly numbers of Ajanta Pharma for Q4FY22?
Answer
Answer
Ajanta Pharma sales revenues were up 14.99% at Rs870.29 crore for the Mar-22 quarter. FY22 full year revenues were up 15.6% at Rs3,341 crore. For Q4FY22, India sales were 13% higher at Rs245 crore. The growth was healthy across verticals and this included cardiology (11%), ophthalmology (25%), dermatology (17%) and pain management (28%). Full year India sales were up 21%, largely driven by growth in pain management segment.
Ajanta Pharma
Rs in Crore
Mar-22
Mar-21
YOY
Dec-21
QOQ
Total Income (Rs cr)
₹ 870.29
₹ 756.84
14.99%
₹ 837.91
3.86%
Net Profit (Rs cr)
₹ 151.21
₹ 159.26
-5.05%
₹ 191.78
-21.15%
Diluted EPS (Rs)
₹ 17.70
₹ 18.40
₹ 22.16
Net Margins
17.37%
21.04%
22.89%
Net profit for Q4FY22 fell -5.05% at Rs151.21 crore with the pressure mounting from a sharp spike in the cost of raw material and manpower. EBITDA fell -20.1% yoy to Rs207 crore even as the EBITDA margins tapered to 24% in Q4FY22. The exports sales at Rs616 crore were largely driven by the emerging markets. Net margins stood at 17.37% in Q4FY22 compared to 21.04% in Q4FY21. The margins were lower on a sequential basis too.